Research News

A new study from researchers at the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) has uncovered a previously unknown consequence of viral infection: too much RNA inside a cell can disrupt its ability to produce energy.

Researchers have identified a potential new strategy to limit the spread of breast cancer to the lungs by targeting the metabolic processes that help cancer cells survive and grow. The study, published in Cancer Biology & Medicine in March 2026, suggests that mitochondrial uncouplers could suppress a key metabolic pathway used by cancer cells and significantly reduce lung metastasis in mouse models.

A common asthma medication improves motor skills and muscle strength in children with congenital myopathies, a group of incurable muscle diseases. In a study, children receiving the drug were able to both walk and stand up more quickly.

A new review in Genes & Diseases highlights FTO, an enzyme involved in RNA modification, as a potentially important biomarker and therapeutic target across gastrointestinal cancers. The article brings together current understanding of FTO in gastric, liver, colorectal and pancreatic cancers, revealing a complex role in which the enzyme can both promote and suppress cancer progression depending on biological context.

A survey of 539 people with Lynch syndrome highlights a gap between evidence supporting aspirin-based cancer prevention and its implementation in clinical practice, despite strong interest in preventive research.

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM). The tumor microenvironment (TME) fosters immunosuppression through tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs), while physical barriers such as dense ECM and abnormal vasculature hinder drug penetration

A team from Flinders University’s Biomedical Nanoengineering Laboratory has found that vanillin has pronounced antioxidant, anti-inflammatory and antibacterial properties, making it a good candidate for wound-healing formulations.

A major prospective clinical trial has identified clinical and molecular characteristics that may help determine which patients with early-stage HER2-positive breast cancer are most likely to achieve a pathologic complete response (pCR) after a shorter, less intensive chemotherapy regimen.

A cancer drug currently being evaluated in clinical trials may work through a different biological mechanism than scientists originally believed, according to a new study led by the University of Sydney in collaboration with Goethe University, the University of Oxford and the Institute of Cancer Research, London.